Hanmi Pharm Co Ltd

MegazoneCloud has begun developing Hanmi Q-Agent, an AI agent that automates Hanmi Pharmaceutical's quality assurance operations, built on its enterprise AI OS AIR Studio. The project is part of the AX One-Stop Voucher Program, through which the Ministry of Science and ICT and the National IT Industry Promotion Agency provide integrated support for AI, cloud, and data in voucher form, and system development started on the 7th. MegazoneCloud will build a retrieval-augmented generation agent for some 4,000 quality documents accumulated by Hanmi Pharmaceutical, retrieving and summarizing them and comparing them against the latest regulations, with the goal of cutting related work time by more than 40 percent. As the response engine, MegazoneCloud fine-tunes Upstage's Korean model Solar to Hanmi Pharmaceutical's GMP domain and deploys it on the AIR Studio-based agent. Hanmi Pharmaceutical leads the consortium, with MegazoneCloud handling AI solution implementation and fine-tuning, Samsung SDS providing the AX infrastructure, and Selectstar performing data processing and third-party verification; the four companies held the 2026 AX One-Stop Voucher Program Hanmi Pharmaceutical Consortium Kickoff on August 28.

Hanmi Pharmaceutical has completed its acquisition of Aptose Biosciences through its wholly owned subsidiary HS North America Ltd. The deal gives Hanmi ownership of Tuspetinib, Aptose's lead asset for acute myeloid leukaemia, marking what Hanmi previously called its first direct entry into North America. Aptose shareholders, excluding Hanmi purchasers and their affiliates, will receive C$2.41 in cash per share. Aptose shares are expected to be delisted from the TSX around July 3, 2026. Hanmi's stock rose 6.04% to 421,500 Korean won on the Korean Stock Exchange.